Two Oral GLP-1 Agonists: Metsera had in-licensed two distinct oral GLP-1 candidates (the active drugs orally bioavailable) with IND-enabling studies or clinical trials imminent ( [11] )
These differences are not unexpected given that SUSTAIN 6 and PIONEER 6 included subjects at high risk of CVD, and PIONEER 5 included subjects with renal impairment
This is important because these tissues often regenerate more slowly than we would like, and insufficient repair can lead to recurring problems
Rotator cuff tendons travel through this small space, where degeneration and impingement often occur
While more research is needed, this highlights the importance of moderation
The most commonly reported side effects are gastrointestinal nausea, mild stomach upset, or changes in bowel habits particularly at the start of treatment or after dose increases